GEFITINIB+NINTEDANIB	
VINCRISTINE+NINTEDANIB	The serum concentration of Nintedanib can be increased when it is combined with Vincristine.
MITOMYCIN+NINTEDANIB	
VINORELBINE+NINTEDANIB	The serum concentration of Nintedanib can be increased when it is combined with Vinorelbine.
PORFIMER+NINTEDANIB	
ETOPOSIDE+NINTEDANIB	The serum concentration of Nintedanib can be increased when it is combined with Etoposide.
IRINOTECAN+NINTEDANIB	
OSIMERTINIB+NINTEDANIB	
DOCETAXEL+DOXORUBICIN	The risk or severity of adverse effects can be increased when Docetaxel is combined with Doxorubicin.
DOCETAXEL+DOXORUBICIN	The metabolism of Doxorubicin can be decreased when combined with Docetaxel.
DOCETAXEL+METHOTREXATE	The risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.
DOCETAXEL+NINTEDANIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Nintedanib.
BRIGATINIB+NINTEDANIB	
DOXORUBICIN+NINTEDANIB	The serum concentration of Nintedanib can be increased when it is combined with Doxorubicin.
METHOTREXATE+NINTEDANIB	
PEMETREXED+NINTEDANIB	
ICOTINIB+NINTEDANIB	
OLMUTINIB+NINTEDANIB	
ALECTINIB+NINTEDANIB	
AFATINIB+NINTEDANIB	
CRIZOTINIB+NINTEDANIB	The serum concentration of Nintedanib can be increased when it is combined with Crizotinib.
RAMUCIRUMAB+NINTEDANIB	
NINTEDANIB+ERLOTINIB	
TOPOTECAN+DOXORUBICIN	The serum concentration of Topotecan can be increased when it is combined with Doxorubicin.
GEFITINIB+VINCRISTINE	The excretion of Vincristine can be decreased when combined with Gefitinib.
GEFITINIB+IRINOTECAN	
GEFITINIB+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Gefitinib.
GEFITINIB+DOXORUBICIN	The serum concentration of Doxorubicin can be increased when it is combined with Gefitinib.
GEFITINIB+METHOTREXATE	
GEFITINIB+RAMUCIRUMAB	
VINCRISTINE+IRINOTECAN	
VINCRISTINE+DOXORUBICIN	The serum concentration of Vincristine can be decreased when it is combined with Doxorubicin.
VINCRISTINE+DOXORUBICIN	The serum concentration of Doxorubicin can be increased when it is combined with Vincristine.
VINCRISTINE+METHOTREXATE	
MITOMYCIN+DOXORUBICIN	The serum concentration of Doxorubicin can be increased when it is combined with Mitomycin.
VINORELBINE+DOXORUBICIN	The serum concentration of Doxorubicin can be increased when it is combined with Vinorelbine.
VINORELBINE+METHOTREXATE	
PORFIMER+DOXORUBICIN	
PORFIMER+METHOTREXATE	
GEMCITABINE+DOXORUBICIN	
GEMCITABINE+METHOTREXATE	
ETOPOSIDE+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Etoposide.
ETOPOSIDE+DOXORUBICIN	The serum concentration of Doxorubicin can be increased when it is combined with Etoposide.
ETOPOSIDE+METHOTREXATE	
IRINOTECAN+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.
IRINOTECAN+DOXORUBICIN	The metabolism of Irinotecan can be decreased when combined with Doxorubicin.
IRINOTECAN+METHOTREXATE	
IRINOTECAN+CISPLATIN	
IRINOTECAN+AFATINIB	
IRINOTECAN+ERLOTINIB	
OSIMERTINIB+DOXORUBICIN	The serum concentration of Doxorubicin can be increased when it is combined with Osimertinib.
OSIMERTINIB+METHOTREXATE	
DOCETAXEL+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Docetaxel.
DOCETAXEL+ERLOTINIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.
BRIGATINIB+DOXORUBICIN	
BRIGATINIB+METHOTREXATE	
BEVACIZUMAB+DOXORUBICIN	Bevacizumab may increase the cardiotoxic activities of Doxorubicin.
BEVACIZUMAB+METHOTREXATE	Bevacizumab may increase the cardiotoxic activities of Methotrexate.
DOXORUBICIN+METHOTREXATE	
DOXORUBICIN+PEMETREXED	
DOXORUBICIN+ICOTINIB	
DOXORUBICIN+CISPLATIN	Cisplatin may increase the nephrotoxic activities of Doxorubicin.
DOXORUBICIN+OLMUTINIB	
DOXORUBICIN+ALECTINIB	The serum concentration of Doxorubicin can be increased when it is combined with Alectinib.
DOXORUBICIN+AFATINIB	The serum concentration of Doxorubicin can be increased when it is combined with Afatinib.
DOXORUBICIN+AFATINIB	The serum concentration of Afatinib can be decreased when it is combined with Doxorubicin.
DOXORUBICIN+CRIZOTINIB	The metabolism of Doxorubicin can be decreased when combined with Crizotinib.
DOXORUBICIN+CRIZOTINIB	The serum concentration of Doxorubicin can be increased when it is combined with Crizotinib.
DOXORUBICIN+RAMUCIRUMAB	
DOXORUBICIN+ERLOTINIB	
METHOTREXATE+PEMETREXED	
METHOTREXATE+ICOTINIB	
METHOTREXATE+CISPLATIN	
METHOTREXATE+OLMUTINIB	
METHOTREXATE+ALECTINIB	
METHOTREXATE+AFATINIB	
METHOTREXATE+CRIZOTINIB	
METHOTREXATE+RAMUCIRUMAB	
METHOTREXATE+ERLOTINIB	
TOPOTECAN+METHOTREXATE	
MITOMYCIN+METHOTREXATE	
DOCETAXEL+PEMETREXED	The risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.
DOCETAXEL+AFATINIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Afatinib.
TOPOTECAN+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Topotecan.
GEFITINIB+MITOMYCIN	
GEFITINIB+VINORELBINE	Gefitinib may increase the neutropenic activities of Vinorelbine.
GEFITINIB+PORFIMER	
GEFITINIB+BRIGATINIB	
GEFITINIB+PEMETREXED	
GEFITINIB+CISPLATIN	
GEFITINIB+ALECTINIB	
GEFITINIB+CRIZOTINIB	The metabolism of Gefitinib can be decreased when combined with Crizotinib.
GEFITINIB+ERLOTINIB	
VINCRISTINE+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.
VINCRISTINE+PEMETREXED	
VINCRISTINE+CISPLATIN	
VINCRISTINE+ERLOTINIB	
MITOMYCIN+IRINOTECAN	
MITOMYCIN+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.
VINORELBINE+IRINOTECAN	
VINORELBINE+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.
PORFIMER+IRINOTECAN	
PORFIMER+DOCETAXEL	
GEMCITABINE+DOCETAXEL	The risk or severity of adverse effects can be increased when Docetaxel is combined with Gemcitabine.
ETOPOSIDE+IRINOTECAN	
IRINOTECAN+OSIMERTINIB	The serum concentration of Irinotecan can be increased when it is combined with Osimertinib.
IRINOTECAN+BRIGATINIB	
IRINOTECAN+BEVACIZUMAB	The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.
IRINOTECAN+PEMETREXED	
IRINOTECAN+ICOTINIB	
IRINOTECAN+OLMUTINIB	
IRINOTECAN+ALECTINIB	
IRINOTECAN+CRIZOTINIB	The metabolism of Irinotecan can be decreased when combined with Crizotinib.
IRINOTECAN+RAMUCIRUMAB	
OSIMERTINIB+DOCETAXEL	The serum concentration of Docetaxel can be increased when it is combined with Osimertinib.
DOCETAXEL+BRIGATINIB	
DOCETAXEL+ICOTINIB	
DOCETAXEL+CISPLATIN	Cisplatin may increase the myelosuppressive activities of Docetaxel.
DOCETAXEL+OLMUTINIB	
DOCETAXEL+ALECTINIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Alectinib.
DOCETAXEL+CRIZOTINIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Crizotinib.
DOCETAXEL+RAMUCIRUMAB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Ramucirumab.
PEMETREXED+ERLOTINIB	
CISPLATIN+ERLOTINIB	
AFATINIB+ERLOTINIB	
RAMUCIRUMAB+ERLOTINIB	
GEFITINIB+ETOPOSIDE	
GEMCITABINE+IRINOTECAN	
PEMETREXED+CISPLATIN	
GEFITINIB+OSIMERTINIB	The serum concentration of Gefitinib can be increased when it is combined with Osimertinib.
GEFITINIB+ICOTINIB	
GEFITINIB+OLMUTINIB	
GEFITINIB+AFATINIB	The serum concentration of Afatinib can be increased when it is combined with Gefitinib.
TOPOTECAN+IRINOTECAN	
ETOPOSIDE+ERLOTINIB	
VINCRISTINE+AFATINIB	The serum concentration of Afatinib can be decreased when it is combined with Vincristine.
VINCRISTINE+AFATINIB	The excretion of Vincristine can be decreased when combined with Afatinib.
MITOMYCIN+ERLOTINIB	
VINORELBINE+ERLOTINIB	
PORFIMER+ERLOTINIB	
BRIGATINIB+ERLOTINIB	
BEVACIZUMAB+ERLOTINIB	Bevacizumab may increase the cardiotoxic activities of Erlotinib.
BEVACIZUMAB+CISPLATIN	Bevacizumab may increase the cardiotoxic activities of Cisplatin.
OSIMERTINIB+ERLOTINIB	The serum concentration of Erlotinib can be increased when it is combined with Osimertinib.
ICOTINIB+ERLOTINIB	
OLMUTINIB+ERLOTINIB	
ALECTINIB+ERLOTINIB	
AFATINIB+RAMUCIRUMAB	
VINCRISTINE+MITOMYCIN	The risk or severity of adverse effects can be increased when Vincristine is combined with Mitomycin.
VINCRISTINE+MITOMYCIN	The excretion of Vincristine can be decreased when combined with Mitomycin.
VINCRISTINE+ETOPOSIDE	The excretion of Vincristine can be decreased when combined with Etoposide.
VINCRISTINE+RAMUCIRUMAB	
MITOMYCIN+AFATINIB	The serum concentration of Afatinib can be increased when it is combined with Mitomycin.
PEMETREXED+AFATINIB	
CISPLATIN+AFATINIB	
GEMCITABINE+CISPLATIN	
TOPOTECAN+VINCRISTINE	The serum concentration of Topotecan can be increased when it is combined with Vincristine.
TOPOTECAN+CISPLATIN	The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.
VINCRISTINE+PORFIMER	
VINCRISTINE+GEMCITABINE	
VINCRISTINE+OSIMERTINIB	The serum concentration of Vincristine can be increased when it is combined with Osimertinib.
VINCRISTINE+BRIGATINIB	
VINCRISTINE+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Vincristine.
VINCRISTINE+ICOTINIB	
VINCRISTINE+OLMUTINIB	
VINCRISTINE+ALECTINIB	The excretion of Vincristine can be decreased when combined with Alectinib.
VINCRISTINE+CRIZOTINIB	The metabolism of Vincristine can be decreased when combined with Crizotinib.
MITOMYCIN+PEMETREXED	
MITOMYCIN+CISPLATIN	
MITOMYCIN+RAMUCIRUMAB	
VINORELBINE+PEMETREXED	
VINORELBINE+CISPLATIN	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.
VINORELBINE+AFATINIB	The serum concentration of Afatinib can be increased when it is combined with Vinorelbine.
PORFIMER+CISPLATIN	
PORFIMER+AFATINIB	
GEMCITABINE+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Gemcitabine.
ETOPOSIDE+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Etoposide.
ETOPOSIDE+CISPLATIN	
ETOPOSIDE+AFATINIB	The serum concentration of Afatinib can be increased when it is combined with Etoposide.
OSIMERTINIB+CISPLATIN	
OSIMERTINIB+AFATINIB	
BRIGATINIB+CISPLATIN	
BRIGATINIB+AFATINIB	
BEVACIZUMAB+PEMETREXED	Bevacizumab may increase the cardiotoxic activities of Pemetrexed.
BEVACIZUMAB+AFATINIB	Bevacizumab may increase the cardiotoxic activities of Afatinib.
PEMETREXED+RAMUCIRUMAB	
ICOTINIB+CISPLATIN	
ICOTINIB+AFATINIB	
CISPLATIN+OLMUTINIB	
CISPLATIN+ALECTINIB	
CISPLATIN+CRIZOTINIB	
CISPLATIN+RAMUCIRUMAB	
OLMUTINIB+AFATINIB	
ALECTINIB+AFATINIB	The serum concentration of Afatinib can be increased when it is combined with Alectinib.
AFATINIB+CRIZOTINIB	The serum concentration of Afatinib can be increased when it is combined with Crizotinib.
VINCRISTINE+VINORELBINE	The excretion of Vincristine can be decreased when combined with Vinorelbine.
VINCRISTINE+CARBOPLATIN	
VINORELBINE+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Vinorelbine.
PORFIMER+PEMETREXED	
CARBOPLATIN+PEMETREXED	
ETOPOSIDE+PEMETREXED	
ETOPOSIDE+ALECTINIB	
ETOPOSIDE+RAMUCIRUMAB	
OSIMERTINIB+PEMETREXED	
OSIMERTINIB+RAMUCIRUMAB	
BEVACIZUMAB+ALECTINIB	Bevacizumab may increase the cardiotoxic activities of Alectinib.
BEVACIZUMAB+RAMUCIRUMAB	Bevacizumab may increase the cardiotoxic activities of Ramucirumab.
PEMETREXED+ICOTINIB	
PEMETREXED+OLMUTINIB	
PEMETREXED+ALECTINIB	
ICOTINIB+RAMUCIRUMAB	
OLMUTINIB+RAMUCIRUMAB	
ALECTINIB+RAMUCIRUMAB	
VINORELBINE+ETOPOSIDE	
PORFIMER+RAMUCIRUMAB	
ETOPOSIDE+CRIZOTINIB	The metabolism of Etoposide can be decreased when combined with Crizotinib.
BRIGATINIB+PEMETREXED	
BEVACIZUMAB+CRIZOTINIB	Bevacizumab may increase the cardiotoxic activities of Crizotinib.
PEMETREXED+CRIZOTINIB	
TOPOTECAN+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Topotecan.
TOPOTECAN+PEMETREXED	
MITOMYCIN+VINORELBINE	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mitomycin.
MITOMYCIN+PORFIMER	
MITOMYCIN+ETOPOSIDE	
MITOMYCIN+OSIMERTINIB	
MITOMYCIN+BRIGATINIB	
MITOMYCIN+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Mitomycin.
MITOMYCIN+ICOTINIB	
MITOMYCIN+OLMUTINIB	
MITOMYCIN+ALECTINIB	
MITOMYCIN+CRIZOTINIB	
VINORELBINE+RAMUCIRUMAB	
PORFIMER+ETOPOSIDE	
PORFIMER+BEVACIZUMAB	
GEMCITABINE+ETOPOSIDE	
GEMCITABINE+PEMETREXED	
CARBOPLATIN+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Carboplatin.
ETOPOSIDE+OSIMERTINIB	The serum concentration of Etoposide can be increased when it is combined with Osimertinib.
ETOPOSIDE+BRIGATINIB	
ETOPOSIDE+ICOTINIB	
ETOPOSIDE+OLMUTINIB	
OSIMERTINIB+BEVACIZUMAB	Bevacizumab may increase the cardiotoxic activities of Osimertinib.
BRIGATINIB+BEVACIZUMAB	
BRIGATINIB+RAMUCIRUMAB	
BEVACIZUMAB+ICOTINIB	
BEVACIZUMAB+OLMUTINIB	
CRIZOTINIB+RAMUCIRUMAB	
PORFIMER+ALECTINIB	
OSIMERTINIB+ALECTINIB	
ICOTINIB+ALECTINIB	
OLMUTINIB+ALECTINIB	
TOPOTECAN+RAMUCIRUMAB	
MITOMYCIN+GEMCITABINE	
VINORELBINE+GEMCITABINE	
VINORELBINE+ALECTINIB	
GEMCITABINE+CARBOPLATIN	
GEMCITABINE+RAMUCIRUMAB	
BRIGATINIB+ALECTINIB	
